SEATTLE--(BUSINESS WIRE)--Dec. 14, 2005--Light Sciences Oncology, Inc., a privately held company focused on the development of Light Infusion Technology(TM) (Litx(TM)) for the treatment of solid tumors, announced today that it has completed an offering of an additional $32 million of its Series A Preferred Stock. The completion follows by two months the initial closing of $35 million of Series A Preferred and brings the total amount of Series A Preferred to $67 million. The funds will be used to undertake a Phase III clinical trial for the treatment of hepatocellular carcinoma (HCC) pursuant to the terms of a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), as well as the initiation of clinical trials in other indications.
